Kalaris Therapeutics to Go Public Via Reverse Merger

Kalaris Therapeutics to Go Public Via Reverse Merger

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On November 7, 2024, Kalaris Therapeutics, a clinical-stage ophthalmology biotech company co-founded by Samsara BioCapital that is developing innovative retinal treatments, announced it had entered into a transformational reverse merger transaction with AlloVir, an allogeneic T cell immunotherapy company, pursuant to which the equityholders of Kalaris will become owners of approximately 75% of the combined company. The transaction is expected to close in the first quarter of 2025.

The WilmerHale team is led by Mark Nylen, Scott Lunin, Ciara Baker and Jason Kropp—with particularly significant contributions from Amanda Albert, Rebecca Nauta, Victoria Peluso, Frank Wang, Michaela Rosen, Shanelle Doher, Carla Gilbertson and Ben Kelsey—and comprises dozens of M&A, capital markets, public company counseling, ECVC, corporate tax, executive compensation and benefits, antitrust, IP, litigation, FDA and other experienced subject matter professionals.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel